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Background-—A higher resting heart rate is associated with an increased probability of cardiovascular complications and
premature death in patients with type 2 diabetes mellitus. The impact of heart rate on the risk of developing microvascular
complications, such as diabetic retinopathy and nephropathy, is, however, unknown. The present study tests the hypothesis that a
higher resting heart rate is associated with an increased incidence and a greater progression of microvascular complications in
patients with type 2 diabetes mellitus.
Methods and Results-—The relation between baseline resting heart rate and the development of a major microvascular event was
examined in 11 140 patients who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modiﬁed
Release Controlled Evaluation (ADVANCE) study. Major microvascular events were deﬁned as a composite of new or worsening
nephropathy or new or worsening retinopathy. Patients with a higher baseline heart rate were at increased risk of a new major
microvascular complication during follow-up (adjusted hazard ratio: 1.13 per 10 beats per minute; 95% conﬁdence interval: 1.07–
1.20; P<0.001). The excess hazard was evident for both nephropathy (adjusted hazard ratio: 1.16 per 10 beats per minute; 95%
conﬁdence interval: 1.08–1.25) and retinopathy (adjusted hazard ratio: 1.11 per 10 beats per minute; 95% conﬁdence interval:
1.02–1.21).
Conclusion-—Patients with type 2 diabetes mellitus who have a higher resting heart rate experience a greater incidence of new-
onset or progressive nephropathy and retinopathy.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT00145925. http://www.advance-trial.com/
static/html/prehome/prehome.asp ( J Am Heart Assoc. 2012;1:e002832 doi: 10.1161/JAHA.112.002832)
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M icroalbuminuria and retinopathy are indicators ofmicrovascular dysfunction, and both predict a poorer
outcome in patients with diabetes1–3 and in individuals with
normal glycemic control.4,5 In particular, even mild degrees of
microalbuminuria are a strong and independent predictor of
major cardiac events in the general population6,7 and among
patients with diabetes4 and hypertension.8 Likewise, several
studies have reported an association between a higher resting
heart rate and an increased risk of cardiovascular complica-
tions in unselected populations and in patients with cardiac
disease.9,10 Recently, we reported a similar relation between
resting heart rate and all-cause death, cardiovascular death,
and major cardiovascular events in patients with type 2
diabetes mellitus.11 This was not attenuated after adjustment
for other factors that inﬂuence heart rate and outcome.11
Although a growing volume of data supports an association
between higher resting heart rate and a greater risk of
macrovascular events in patients with type 2 diabetes, the
impact of heart rate on the risk of developing microvascular
complications, such as diabetic retinopathy and nephropathy,
is unknown. There are, however, reasons to suspect that an
elevated resting heart rate might predict microvascular
outcomes in this setting. In patients with hypertension, a
higher resting heart rate has been associated with a greater
prevalence of microalbuminuria,12,13 a relation that was
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maintained after correction for a variety of potential
confounding factors. Similarly, a weak, but signiﬁcant and
independent, association between baseline resting heart rate
and urinary albumin:creatinine ratio (ACR) was recently
reported in the Randomised Olmesartan and Diabetes Micro-
albuminuria Prevention study.14 However, not all existing data
support an association between prevalent heart rate and
albuminuria,15 and the cross-sectional results that are
currently available cannot address the relation between heart
rate and incident or progressive microalbuminuria.
A higher resting heart rate has been reported in patients
with diabetic retinopathy16 and could be due to the relation
between retinopathy and autonomic dysfunction. Once again,
however, the importance of heart rate in the development or
progression of diabetic eye disease remains unclear. Using
data from the Action in Diabetes and Vascular Disease:
Preterax and Diamicron Modiﬁed Release Controlled Evalua-
tion (ADVANCE) study (ClinicalTrials.gov No. NCT00145925),
we tested the hypothesis that a higher resting heart rate
would be associated with both an increased incidence and a
greater progression of microvascular complications in
patients with type 2 diabetes mellitus.
Methods
The ADVANCE study recruited 11 140 patients with type 2
diabetes mellitus from 215 centers in 20 countries between
June 2001 and March 2003.17,18 The study made 2 random-
ized comparisons: (1) a double-blind assessment of the
efﬁcacy of a ﬁxed-combination perindopril–indapamide (2
mg/0.625 mg for 3 months, increasing, if tolerated, to 4 mg/
1.25 mg) versus placebo and (2) an open-label evaluation of an
intensive glucose-lowering regimen with modiﬁed-release
gliclazide, with a target hemoglobin A1c of ≤6.5%, versus
standard guideline-based glycemic control. The study was
approved by the local ethics committee for each participating
center, and all participants provided written informed consent.
Participants were ≥55 years of age and had been diagnosed
with type 2 diabetes mellitus after the age of 30 years. In
addition, they were required to have a history of cardiovas-
cular disease or ≥1 additional cardiovascular risk factor.19
Detailed study methods19 and the main results17,18 of the
ADVANCE study have been reported previously.
Heart rate was measured at the same time as blood
pressure with a digital monitor (Omron HEM-705CP, Omron
Healthcare Inc, Lake Forest, IL). Recordings were made after
the patient had been resting in a seated position for a
minimum of 5 minutes. Three readings were taken, and the
mean of the latter 2 was used. Weight, height, urinary ACR,
serum creatinine, fasting lipid levels, and glycosylated hemo-
globin also were measured at baseline.
The present study assesses the relation between resting
heart rate and the development of a major microvascular event
(a coprimary endpoint of the ADVANCE study) over the length of
the trial (median follow-up of 4.4 years). Major microvascular
events were deﬁned, a priori, as a composite of new or
worsening nephropathy or retinopathy. The former was deﬁned
as ≥1 of the following: the development of macroalbuminuria,
deﬁned as a urinary ACR of >300 lg albumin per milligram of
creatinine (conﬁrmed by 2 positive results); doubling of the
serum creatinine level to ≥200 lmol/L (unless in the context of
acute illness, with subsequent recovery of renal function, or in
the context of the terminal phase of illness); the need for renal
replacement therapy due to diabetic kidney disease, in the
absence of another acute medical cause that could require
transient dialysis; or death due to renal disease. Participants
had their creatinine levels measured as part of the study
protocol at baseline, 4 months, and 1 year and annually
thereafter until completion of the study. Renal function was
checked out with these time points at the discretion of their
treating clinicians. Urinary ACR was measured locally as part of
the study protocol at baseline, 2 years, 4 years, and completion
of the study. Neworworsening retinopathywas deﬁned as≥1 of
the following: the development of proliferative retinopathy
(identiﬁed by the incidence of new blood vessels on the disc or
elsewhere, vitreous hemorrhage, preretinal hemorrhage,
ﬁbrous proliferations on the disc or elsewhere in a participant
known not to have this condition at entry); macular edema
(characterized by a retinal thickening within 1 disc diameter of
the macular center, in a participant known not to have this
condition at entry); diabetes-related blindness (corrected visual
acuity 3/60 or worse, persisting for ≥3 months and known to
not be due to nondiabetic causes, in a participant known not to
have this condition at entry); or the use of retinal photocoag-
ulation therapy. Participants underwent formal eye examination
and visual acuity testing at baseline, 2 years, 4 years, and
completion of the study.
Secondary endpoints were the individual components of
the primary outcome (new or worsening nephropathy and new
or worsening retinopathy). An Endpoint Adjudication Commit-
tee, unaware of treatment allocation, reviewed source docu-
mentation for all individuals who had a suspected primary
endpoint of the ADVANCE study. This included all the
microvascular endpoints considered in the present analyses.
Statistical Analyses
Baseline resting heart rate was considered both as a continuous
variable and after grouping into approximately equal ﬁfths
according to its quintiles. Trends in baseline characteristics
across the ﬁfths of heart rate were compared with linear and
logistic regression. Cox regression analyses were used to
calculate hazard ratios with 95% conﬁdence intervals. These
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were performed in models adjusted for age, sex, ADVANCE
study blood pressure treatment arm, and ADVANCE study
glycemic control arm and in models adjusted for multiple
baseline covariates (age, sex, ADVANCE study randomized
treatment, body mass index, duration of diabetes, glycosylated
hemoglobin, estimated glomerular ﬁltration rate, urinary ACR,
systolic blood pressure, diastolic blood pressure, history of a
prior macrovascular complication of diabetes [myocardial
infarction, stroke, hospital admission for a transient ischemic
attack, hospital admission for unstable angina, coronary revas-
cularization, peripheral revascularization or amputation second-
ary to peripheral vascular disease], history of hospitalization for
heart failure, participation in moderate or vigorous exercise for
>15 minutes at least once weekly, current cigarette smoking,
total cholesterol, triglycerides, atrial ﬁbrillation, treatment with
calcium channel blockers, and treatment with b-blockers).
Interactions were tested by adding appropriate terms to Cox
models. Linearity was assessed by comparing the categorical
model with the linear trend model.20 It is possible that death
during follow-upmight affect the association between heart rate
and the outcomes of interest. Therefore, we estimated subdis-
tribution hazard ratios after correcting for the competing risk of
death according to the methods of Fine and Gray.21 Odds ratios
and 95% conﬁdence intervals for albuminuria at baseline and
microvascular diabetic eye disease at baseline among the ﬁfths
of heart rate were estimated by logistic regression. Analyses
were performed in SAS v9.2 (SAS Institute, Cary, NC), SPSS v18
(SPSS Inc., Chicago, IL), and Stata 11 (Statacorp LP, College
Station, TX), and all reported P values are 2 sided, with the 5%
threshold used to determine signiﬁcance.
Results
Of the 11 140 patients randomized into the ADVANCE study,
2 individuals did not have their baseline resting heart rate
recorded. The remaining 11 138 patients are included in the
present analyses. Participants had a mean age of 66 years,
and 58% were male. The mean heart rate in the study
population, ± standard deviation, was 74±12 beats per
minute, with a range of 33 to 140 beats per minute. The
characteristics of the study population according to baseline
resting heart rate are shown in Table 1.
Heart Rate and Microvascular Disease at Baseline
At baseline, 793 patients (7.1%) had microvascular diabetic eye
disease (proliferative retinopathy, retinal photocoagulation
therapy, macular edema, or blindness in at least one eye
thought to be due to diabetes). These individuals had a mean
resting heart rate of 76±12 beats per minute, compared to
74±12 beats per minute in patients without microvascular eye
disease at baseline (P<0.001). At the time of randomization,
7376 participants (66.2%) had normal urinary albumin levels
(urinary ACR <3.4 mg/mmol [<30 lg/mg]), 2861 (25.7%) had
microalbuminura (urinary ACR 3.4–33.9 mg/mmol [30–300
lg/mg]), and 401 (3.6%) had macroalbuminuria (urinary ACR
>33.9 mg/mmol [>300 lg/mg]). Five hundred patients (4.5%)
had missing ACR data. Figure 1 shows the prevalence of
albuminuria according to baseline resting heart rate (P for trend
<0.001). The age- and sex-adjusted and multivariable-adjusted
odds ratios for (a) albuminuria and (b) microvascular diabetic
eye disease at baseline according to ﬁfth of resting heart rate
(with the lowest ﬁfth as the reference) are shown in Tables 2
and 3. These data conﬁrm a cross-sectional association
between baseline heart rate and both complications.
Heart Rate and Microvascular Complications
During a median follow-up of 4.4 years, 916 patients (8.2%)
experienced a major microvascular event. Three hundred and
ninety-seven patients (3.6%) developed new or worsening
nephropathy, and 575 (5.2%) developed new or worsening
retinopathy. Fifteen patients were lost to follow-up (vital status
unknown) at the end of follow-up and were censored at the last
follow-up assessment. In addition, 879 patients (7.9%) died
during follow-up. Patients who died before the occurrence of
each outcomewere censored at the time of death (786 patients
for major microvascular events, 840 for retinopathy, and 817
for nephropathy were censored at the date of death).
A higher baseline resting heart rate was associated with a
greater risk of developing a major microvascular complication
during follow-up (Table 4). After adjustment for age, sex, and
randomized treatment, a 10-beats-per-minute increase in base-
line resting heart ratewas associatedwith an 18% increase in the
observed hazard. This remained after adjustment for potential
confounders. The excess hazard was apparent for both compo-
nents of the primary outcome (nephropathy and retinopathy) but
was greater for the development of new or worsening diabetic
eye disease (Table 4), where a clear linear relation is apparent. In
contrast, the relation between heart rate and nephropathy is
nonlinear, with the excess hazard, relative to the lowest ﬁfth,
only seen clearly in patients with a heart rate in the upper ﬁfth
(Table 4). The risk estimates were essentially unchanged even
after correction for the competing risk of death (data not shown).
The increased risk of microvascular complications associ-
ated with a higher heart rate was observed in both sexes, in
patients who had suffered a prior major macrovascular compli-
cation (myocardial infarction, stroke, hospital admission for a
transient ischemic attack, hospital admission for angina,
coronary revascularization, peripheral revascularization, or
amputation secondary to peripheral vascular disease) and in
those who had not (Figure 2). Similarly, an excess hazard was
seen in patients bothwith andwithout preexistingmicrovascular
disease (Figure 2). It alsowas observed in patientswhowere not
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on a b-blocker but not in those who were on a b-blocker
(Figure 2), although there was no statistical evidence of an
interaction. A higher heart rate was associated with a greater
risk of amicrovascular complication both in patientswhowere in
sinus rhythm and those with atrial ﬁbrillation (on an electrocar-
diogram performed either at baseline or previously22).
Discussion
The present study demonstrates that a higher resting heart rate
predicts a greater risk of future microvascular complications in
patientswith type2diabetesmellitus. As far asweare aware, this
has not been shown previously. The excess hazard associated
with a higher heart rate is independent ofmany other factors that
can inﬂuence heart rate and affect outcome in this setting. The
association is particularly apparent for the occurrence or
worsening of diabetic eye disease but is also evident for the
occurrence or worsening of diabetic nephropathy.
Heart Rate and Microvascular Events
The relation between higher heart rates and major adverse
cardiac events, such as myocardial infarction, cardiac death,
and hospitalization with heart failure, is now well recognized.23
Indeed, we recently reported in ADVANCE that a higher heart
rate was a strong and independent predictor of all-cause death
and major cardiovascular complications, including cardiovas-
cular death, myocardial infarction, and stroke.11 In contrast,
there are limited prior data, almost entirely cross sectional,
assessing the relation between heart rate and microvascular
disease. In patients with hypertension, Bohm and colleagues12
reported that a higher heart rate is associated with increasedTa
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Figure 1. Prevalence of albuminuria according to ﬁfths of heart
rate at baseline.
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prevalence and severity of microalbuminuria. This relation was
observed regardless of treatment with b-blockers12 and
irrespective of whether the patient had a history of atrial
ﬁbrillation.13 However, in a recently reported analysis of The
PROspective pioglitAzone Clinical Trial In macroVascular
Events, a multicenter double-blind assessment of the effects
of pioglitazone versus placebo on major cardiovascular events
in patients with type 2 diabetes and a history of macrovascular
disease, no association was observed between resting heart
rate and microalbuminuria.15 Despite this, heart rate and
microalbuminuria were each independently predictive of the
composite endpoint of all-cause death, myocardial infarction,
and stroke in this study.15
Neither of the aforementioned studies13,15 assessed the
relation between heart rate and incident albuminuria. Two
recent prospective studies have, however, identiﬁed a higher
heart rate as a predictor of renal dysfunction in the general
population.24,25 In the Atherosclerosis Risk in Communities
(ARIC) Study, the hazard of developing end-stage renal disease
was almost doubled among patients with a resting heart rate in
the upper quarter, when compared to the remaining subjects,
during amedian of 16 years’ follow-up.24 Similarly, in a cohort of
subjects participating in a Japanese health screening program,
a higher heart rate was associated with a greater risk of
declining estimated glomerular ﬁltration rate and of developing
dipstick proteinuria (≥1) during 5 years of follow-up.25
An association between a higher resting heart rate and
prevalent retinopathy in patients with diabetes has been
reported previously,16 although not consistently.26,27 In the
Wisconsin Epidemiological Study of Diabetic Retinopathy,
although patients with a higher resting heart rate had a
greater risk of incident macular edema and progressive
diabetic retinopathy over a 4-year period, this was attenuated
and was nonsigniﬁcant after correction for other factors,
including age, duration of diabetes, glycosylated hemoglobin,
and blood pressure.28 In contrast, in our much larger cohort,
followed up for 4.4 years, we have observed strong and
independent associations between resting heart rate and
incident and progressive diabetic eye disease, even after
correction for a wide range of potential confounding factors
(including all of those mentioned above). Apart from differ-
ences in power, the discrepant results could reﬂect variances
in the study populations and protocols. The Wisconsin
Epidemiological Study of Diabetic Retinopathy recruited a
community-based cohort with a high prevalence of younger,
insulin-requiring patients, and the incidence and progression
of retinopathy was determined with fundus photography.
Potential Mechanisms
Although a higher resting heart rate predicts a greater
prevalence of albuminuria and diabetic eye disease at
Table 2. Albuminuria at Baseline According to Fifth of Resting Heart Rate
Adjusted for Age and Sex Fully Adjusted*
Odds Ratio 95% Conﬁdence Interval P Odds Ratio 95% Conﬁdence Interval P
Lowest ﬁfth 1 Reference … 1 Reference …
2nd ﬁfth 1.10 0.96–1.26 0.17 1.13 0.98–1.30 0.10
3rd ﬁfth 1.09 0.95–1.25 0.24 1.08 0.93–1.25 0.33
4th ﬁfth 1.34 1.17–1.54 <0.001 1.27 1.10–1.47 0.001
Highest ﬁfth 1.50 1.31–1.71 <0.001 1.35 1.17–1.56 <0.001
*Adjusted for age, sex, body mass index, duration of diabetes, glycosylated hemoglobin, estimated glomerular ﬁltration rate, systolic blood pressure, diastolic blood pressure, history of
hospitalization for heart failure, prior macrovascular disease (see text), current cigarette smoking, participation in moderate or vigorous exercise for >15 minutes at least once weekly, total
cholesterol, triglyceride level, atrial ﬁbrillation, use of calcium channel blockers, and use of b-blockers.
Table 3. Microvascular Diabetic Eye Disease at Baseline According to Fifth of Resting Heart Rate
Adjusted for Age and Sex Fully Adjusted*
Odds Ratio 95% Conﬁdence Interval P Odds Ratio 95% Conﬁdence Interval P
Lowest ﬁfth 1 Reference … 1 Reference …
2nd ﬁfth 1.27 0.99–1.62 0.06 1.29 0.99–1.67 0.06
3rd ﬁfth 1.22 0.95–1.57 0.13 1.19 0.91–1.57 0.21
4th ﬁfth 1.38 1.08–1.77 0.01 1.38 1.06–1.81 0.02
Highest ﬁfth 1.62 1.28–2.06 <0.001 1.59 1.22–2.07 <0.001
*Adjusted for variables listed in footnote to Table 2, plus urinary albumin:creatinine ratio.
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baseline and higher risk of subsequent microvascular events,
the results could reﬂect an association between heart rate
and other factors that might mediate microvascular disease.
There are, however, several plausible mechanisms by which
an elevated heart rate might predispose to such complica-
tions.
It has been suggested that a higher heart rate might
promote microalbuminuria because of increased exposure of
the glomerulus to arterial pressure waves.12 A similar mech-
anism also might explain the relation between more rapid
heart rates and ocular disease. An increased heart rate also
has a variety of direct detrimental cardiovascular conse-
quences. These include unfavorable effects on endothelial
function and proatherosclerotic activity,29 which are important
factors in the progression of nephropathy and retinopathy.30–32
A higher heart rate also is associated with factors such as
Table 4. Effects of Heart Rate on Major Microvascular Outcomes
No. Events/No. at Risk
Adjusted for Age, Sex, and Randomized
Treatment Fully Adjusted*
HR (95% CI) P HR (95% CI) P
Major microvascular events
Heart rate per 10 bpm 916/11 138 1.18 (1.12–1.24) <0.001 1.13 (1.07–1.20) <0.001
Heart rate ﬁfths
Lowest ﬁfth (33–63 bpm) 132/2066 1.00 (reference) 1.00 (reference)
2nd ﬁfth (64–70 bpm) 184/2393 1.23 (0.99–1.54) 0.07 1.27 (1.00–1.61) 0.047
3rd ﬁfth (71–76 bpm) 161/2178 1.19 (0.94–1.49) 0.15 1.15 (0.90–1.47) 0.27
4th ﬁfth (77–83 bpm) 194/2195 1.45 (1.16–1.81) 0.001 1.39 (1.09–1.76) 0.008
Highest ﬁfth (84–140 bpm) 245/2306 1.78 (1.44–2.20) <0.001 1.63 (1.29–2.06) <0.001
P for trend <0.001 <0.001
P for nonlinearity 0.37 0.27
New or worsening retinopathy
Heart rate per 10 bpm 575/11 138 1.22 (1.14–1.30) <0.001 1.16 (1.08–1.25) <0.001
Heart rate ﬁfths
Lowest ﬁfth (33–63 bpm) 71/2066 1.00 (reference) 1.00 (reference)
2nd ﬁfth (64–70 bpm) 96/2393 1.15 (0.84–1.56) 0.38 1.13 (0.82–1.57) 0.46
3rd ﬁfth (71–76 bpm) 115/2178 1.51 (1.12–2.03) 0.007 1.44 (1.05–1.98) 0.02
4th ﬁfth (77–83 bpm) 139/2195 1.82 (1.36–2.43) <0.001 1.67 (1.23–2.28) 0.001
Highest ﬁfth (84–140 bpm) 154/2306 1.94 (1.46–2.57) <0.001 1.72 (1.26–2.34) <0.001
P for trend <0.001 <0.001
P for nonlinearity 0.70 0.69
New or worsening nephropathy
Heart rate per 10 bpm 397/11 138 1.13 (1.04–1.22) 0.003 1.11 (1.02–1.21) 0.01
Heart rate ﬁfths
Lowest ﬁfth (33–63 bpm) 69/2066 1.00 (reference) 1.00 (reference)
2nd ﬁfth (64–70 bpm) 93/2393 1.24 (0.91–1.70) 0.18 1.45 (1.04–2.02) 0.03
3rd ﬁfth (71–76 bpm) 58/2178 0.86 (0.60–1.21) 0.38 0.90 (0.61–1.31) 0.57
4th ﬁfth (77–83 bpm) 69/2195 1.05 (0.75–1.47) 0.78 1.10 (0.76–1.58) 0.61
Highest ﬁfth (84–140 bpm) 108/2306 1.60 (1.18–2.17) 0.003 1.61 (1.15–2.26) 0.006
P for trend 0.02 0.05
P for nonlinearity 0.005 0.003
HR indicates hazard ratio; CI, conﬁdence interval.
*Adjusted for age, sex, randomized treatment for blood pressure, randomized treatment for glucose, body mass index, duration of diabetes, glycosylated hemoglobin, prior macrovascular
complication of diabetes (see text), estimated glomerular ﬁltration rate, urinary albumin:creatinine ratio, systolic blood pressure, diastolic blood pressure, history of hospitalization for heart
failure, regular exercise (see text), current cigarette smoking, total cholesterol, triglycerides, atrial ﬁbrillation, use of calcium channel antagonists, and use of b-blockers.
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Hazard
(a)
(b)
 ra?o for 10bpm increase in heart rate
Sex
HR (95% CI) P
P for
interac?on
Men 1 16 (1 08 to 1 24) <0 001 0 83
Prior macrovascular disease
. . . . .
11.1nemoW  (1.01 to 1.22) 0.03
31.1oN  (1.06 to 1.21) <0.001 0.85
Yes 1 14 (1 03 to 1 25) 0 01
Treatment with beta blocker
Prior microvascular disease
.  . . .
40.1(11.1oN  to 1.18) 0.002 0.36
80.1(12.1seY  to 1.36) 0.001
   
Atrial fibrilla?on
80.1(51.1oN  to 1.23) <0.001 0.23
49.0(60.1seY  to 1.20) 0.35
No 1.13 (1.06 to 1.19) <0.001 0.68
Randomised treatment for blood pressure
  
42.1seY  (1.00 to 1.53) 0.048
40.1(21.1obecalP  to 1.22) 0.004 0.85
Perindopril/Indap 41.1edima  (1.05 to 1.24) 0.001
Randomised treatment for glucose
60.1(51.1dradnatS  to 1.24) <0.001 0.94
700.0)22.1ot30.1(21.1evisnetnI
Hazard ra?o
0.5 1.0 2.0
70.1(31.1llarevO  to 1.20) <0.001
Hazard ra?o for highest vs. lowest fi?h of heart rate
Sex
HR (95% CI) P
P for
interac?on
Men 1 80 (1 35 to 2 40) <0 001 0 73
Prior macrovascular disease
. .  . . .
59.0(44.1nemoW  to 2.16) 0.08
71.1(65.1oN  to 2.09) 0.003 0.28
Yes 1 69 (1 13 to 2 54) 0 01
Treatment with beta blocker
Prior microvascular disease
. .  . .
91.1(65.1oN  to 2.03) 0.001 0.86
92.1(01.2seY  to 3.43) 0.003
   
Atrial fibrilla?on
53.1(97.1oN  to 2.38) <0.001 0.11
56.0(11.1seY  to 1.90) 0.71
No 1.60 (1.25 to 2.03) <0.001 0.60
Randomised treatment for blood pressure
 
98.0(81.2seY  to 5.34) 0.09
65.1obecalP  (1.14 to 2.15) 0.006 0.99
Perindopril/Indap 47.1edima  (1.23 to 2.45) 0.002
Randomised treatment for glucose
02.1(66.1dradnatS  to 2.30) 0.002 0.53
51.1(16.1evisnetnI  to 2.25) 0.006
Hazard ra?o
92.1(36.1llarevO  to 2.06) <0.001
2.0 0.40.15.0
Figure 2. Effects of baseline heart rate on major microvascular events in subgroups. Adjusted for age, sex, randomized treatment for blood
pressure, randomized treatment for glucose, body mass index, duration of diabetes, glycosylated hemoglobin, prior macrovascular complication of
diabetes (see text), estimated glomerular ﬁltration rate, urinary albumin:creatinine ratio, systolic blood pressure, diastolic blood pressure, history
of hospitalization for heart failure, regular exercise (see text), current cigarette smoking, total cholesterol, triglycerides, atrial ﬁbrillation, use of
calcium channel antagonists, and use of b-blockers. Where relevant, the variable used for subgrouping was excluded from the model. Centers of
boxes are placed at the estimates of adjusted hazard ratio (HR) for each subgroup. Areas of the boxes are proportional to the reciprocal of the
variance of the estimates. Horizontal lines represent 95% conﬁdence intervals (CI). Vertical broken lines indicate the estimate of overall adjusted
hazard ratio. The widths of diamonds represent 95% CI. bpm indicates beats per minute.
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obesity, higher blood pressure, a proatherosclerotic lipid
proﬁle, and reduced physical activity,10,33 all of which are
associated with an increased risk of microvascular complica-
tions and are targets for intervention to improve outcome in
patients with diabetes mellitus.34 Finally, a faster resting heart
rate is a characteristic feature of autonomic neuropathy, which
is in turn associated with an increased prevalence of other
complications, such as nephropathy and retinopathy.35 It is
possible, therefore, that the observed relation between heart
rate and microvascular events is mediated at least in part by
sympathetic overactivity, although correlations between heart
rate and measures of sympathetic tone are relatively weak.36
Whenbaroreﬂex control of heart rate is assessedby sensitive
methods, abnormalities are apparent at an early stage in
patients with diabetes. These changes predate obvious diabetic
complications and evidence of autonomic dysfunction that can
be detected by conventional methods.37,38 Intriguingly, a higher
heart rate per se also has been shown to predict an increased
risk of developing incident diabetes.39 This could reﬂect
physical deconditioning and other factors that predispose to
developing diabetes but reinforces the complex interrelations
among heart rate, neural mechanisms, and metabolic control.
It could be that the observed hazard associated with a
higher heart rate is due to a combination of mechanisms and
that the importance of each varies among individuals.
Likewise, the mechanisms could have synergistic effects.
For example, a higher heart rate might result in direct
microvascular damage, but this could be accentuated by the
presence of hypertension. In particular, elevated nocturnal
blood pressure in diabetes is associated with incident
microalbuminuria40 and progressive nephropathy.41 The risk
attributable to this “nondipping” pattern might not be
conveyed in the measured daytime blood pressure and might
be magniﬁed by a higher resting heart rate, which increases
exposure of the microvasculature to the elevated pressures.
In summary, the mechanisms by which a higher resting
heart rate predicts an increased risk of microvascular
complications in type 2 diabetes mellitus are unclear, and it
could be that several interrelated processes are involved. One
potential method of assessing whether there might be a direct
relation would be to assess the effects of a pure rate-limiting
drug, such as ivabradine, on microvascular outcomes.
Differences in the Observed Relation Between
Heart Rate and Eye Disease and Nephropathy
In this analysis, the relation between resting heart rate and
the risk of developing diabetic eye disease seems stronger
than the association with incident nephropathy. In addition, in
contrast to retinopathy, the data suggest that the relation
between heart rate and renal disease is nonlinear, with the
excess hazard clearly seen only in patients with a resting
heart rate in the upper ﬁfth. Similarly, in the baseline, cross-
sectional data, the increased prevalence of microalbuminuria
is most obvious in patients with heart rates in the upper two
ﬁfths. This raises the possibility that the relation between
heart rate and microvascular disease could vary in differing
vascular beds. This is not unexpected, given that the effects of
blood pressure–lowering treatment and more intensive
glycemic control in the ADVANCE study were more apparent
in the kidney than in the eye. Similar differential effects of
treatment on differing microvascular complications have been
observed in other large studies.42,43 Whether this reﬂects
differing pathophysiological mechanisms, is a chance ﬁnding,
or is due to the deﬁnitions used and the relatively short
duration of follow-up is not clear.
Strengths and Limitations
The present study explores the relation between heart rate
and future microvascular complications in patients with type 2
diabetes mellitus in a large population recruited from 20
countries and with diverse ethnic backgrounds, which was
well characterized and followed up closely. The primary
endpoint of this epidemiological evaluation was a coprimary
endpoint of the main ADVANCE study, and all components of
it were independently adjudicated according to predeﬁned
criteria. Nevertheless, it has the limitations inherent in any
such post hoc analysis. Although the large study population
ensures considerable statistical power and allows reliable
correction for many potential confounding factors, it is not
possible to fully correct for all possible confounders. In
particular, autonomic function was not assessed at baseline.
Conclusion
Patients with type 2 diabetes mellitus who have a higher
resting heart rate have a greater prevalence of microalbu-
minuria and diabetic eye disease. They also experience a
greater incidence of new-onset or progressive nephropathy
and retinopathy, which suggests that an increased heart rate
might be a potential mediator of these outcomes. Further
work is required to assess this and to determine whether
lifestyle measures or pharmacological therapies that can slow
heart rate might reduce the risk of microvascular complica-
tions. In particular, the beneﬁts of heart rate reduction in the
prevention of progressive diabetic retinopathy deserve further
attention.
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